Revenue during the quarter grew 6.01 percent to $255.66 million from $241.16 million in the previous year period. Gross margin for the quarter expanded 391 basis points over the previous year period to 66.59 percent. Total expenses were 84.05 percent of quarterly revenues, down from 90.04 percent for the same period last year. This has led to an improvement of 599 basis points in operating margin to 15.95 percent.

Operating income for the quarter was $40.77 million, compared with $24.01 million in the previous year period.

However, the adjusted EBITDA for the quarter stood at $66.46 million compared with $56.67 million in the prior year period. At the same time, adjusted EBITDA margin improved 250 basis points in the quarter to 26 percent from 23.50 percent in the last year period.

"We were pleased with our performance in 2016, which resulted in full-year organic revenue growth of 9% and full-year adjusted gross margin of 69.5%," said Peter Arduini, Integra's President and Chief Executive Officer. "We look forward to a transformative 2017 as we integrate two of the largest acquisitions in the Company's history."

For fiscal year 2017, Integra Lifesciences Holdings Corp expects revenue to be in the range of $1,120 million to $1,140 million. The company forecasts net income to be in the range of $39.30 million to $43.80 million and projects adjusted net income to be in the range of $149.10 million to $153.60 million. It projects diluted earnings per share to be in the range of $0.49 to $0.55 and  projects diluted earnings per share to be in the range of $1.88 to $1.94 on adjusted basis.